Heidelberg Pharma AG (WBO:HPHA) Beta: N/A (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:HPHA Heidelberg Pharma AG WBO:HPHA
10 GF Score
Price €2.55
GF Value €2.91
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-16), Heidelberg Pharma AG's Beta is Not available.

Heidelberg Pharma AG  (WBO:HPHA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Heidelberg Pharma AG Beta Related Terms

Heidelberg Pharma AG Beta Historical Data

* Premium members only.

The historical data trend for Heidelberg Pharma AG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG Beta Chart

Heidelberg Pharma AG Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Heidelberg Pharma AG Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WBO:HPHA
10GF Score
Heidelberg Pharma AG WBO:HPHA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heidelberg Pharma AG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.55 is trading 12.4% below its estimated GF Value™ of €2.91. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for WBO:HPHA:

  • Beta: N/A
  • GF Value™: €2.91 vs. price of €2.55 (12.4% below fair value)
  • GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heidelberg Pharma AG Business Description

Other Exchanges 0QW5:UKHPHA:Germany
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
10GF Score

Get the complete analysis for WBO:HPHA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€2.91
GF Value